See more : DL Holdings CO., LTD. (000215.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Diaceutics PLC (DIUXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Diaceutics PLC, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Welcast Steels Limited (ZWELCAST.BO) Income Statement Analysis – Financial Results
- Otonomo Technologies Ltd. (OTMO) Income Statement Analysis – Financial Results
- Ensurge Micropower ASA (ENMPF) Income Statement Analysis – Financial Results
- Standard Chem & Pharm CO., LTD. (1720.TW) Income Statement Analysis – Financial Results
- WLM Participações e Comércio de Máquinas e Veículos S.A. (WLMM4.SA) Income Statement Analysis – Financial Results
Diaceutics PLC (DIUXF)
About Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX patient journey that enables pharma customers to complete a longitudinal analysis of biomarker testing journeys of individual patients, which identifies opportunities for earlier testing and treatment; DXRX lab benchmarking that enables laboratories to gain competitive edge and compare key criteria to others in the industry providing metrics, such as disease, testing and methodology, market share, turnaround time, and laboratory leadership in these areas; DXRX test reimbursement, which enables pharma customers to engage with laboratories to fund the introduction of novel companion diagnostics, as well as reducing the lag time in test adoption; and DXRX test signal that delivers a real-time alert of a testing event, which allows pharma customers to identify therapeutically actionable patients in the previous weeks. In addition, it offers diagnostic landscape, planning, implementation, and tracking services; and consulting services for precision medicine diagnostics. Further, the company provides test standardization, test quality assessment, test report optimization, laboratory tech support, test access and reimbursement, laboratory training, and educational resources services. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 23.70M | 19.50M | 13.94M | 12.70M | 13.44M | 10.37M | 7.37M | 4.59M |
| Cost of Revenue | 3.99M | 2.76M | 3.21M | 3.23M | 3.13M | 3.57M | 2.48M | 1.93M |
| Gross Profit | 19.71M | 16.74M | 10.73M | 9.46M | 10.31M | 6.80M | 4.89M | 2.66M |
| Gross Profit Ratio | 83.15% | 85.83% | 76.97% | 74.54% | 76.70% | 65.57% | 66.31% | 57.86% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 78.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 22.78M | 16.28M | 10.38M | 10.02M | 8.39M | 5.52M | 4.18M | 1.95M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.78M | 16.28M | 10.38M | 10.02M | 8.39M | 5.52M | 4.18M | 1.95M |
| Other Expenses | -60.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.72M | 16.17M | 10.18M | 9.73M | 8.22M | 5.40M | 3.99M | 1.77M |
| Cost & Expenses | 26.72M | 18.93M | 13.39M | 12.97M | 11.35M | 8.97M | 6.47M | 3.71M |
| Interest Income | 646.00K | 111.00K | 88.00K | 27.00K | 2.63K | 0.00 | 0.00 | 33.00 |
| Interest Expense | 66.00K | 122.00K | 88.00K | 41.00K | 222.40K | 301.58K | 110.74K | 87.99K |
| Depreciation & Amortization | 4.77M | 3.01M | 1.80M | 809.00K | 284.86K | 117.68K | 26.58K | 167.53K |
| EBITDA | 2.40M | 2.08M | 1.52M | 178.00K | 1.00M | 1.52M | 927.83K | 1.05M |
| EBITDA Ratio | 10.13% | 18.94% | 16.85% | 4.46% | 17.67% | 14.69% | 12.59% | 22.88% |
| Operating Income | -3.02M | 575.00K | 550.00K | -658.00K | 740.42K | 1.20M | 901.25K | 882.29K |
| Operating Income Ratio | -12.73% | 2.95% | 3.94% | -5.18% | 5.51% | 11.58% | 12.23% | 19.23% |
| Total Other Income/Expenses | 580.00K | -11.00K | -88.00K | -24.00K | -243.00K | -323.66K | -116.39K | -97.31K |
| Income Before Tax | -2.44M | 564.00K | 462.00K | -682.00K | 497.32K | 877.26K | 784.86K | 784.98K |
| Income Before Tax Ratio | -10.29% | 2.89% | 3.31% | -5.37% | 3.70% | 8.46% | 10.65% | 17.11% |
| Income Tax Expense | -692.00K | -160.00K | -99.00K | -945.00K | 99.44K | 244.96K | 121.66K | 37.84K |
| Net Income | -1.75M | 724.00K | 561.00K | 263.00K | 398.00K | 632.31K | 663.19K | 747.14K |
| Net Income Ratio | -7.37% | 3.71% | 4.02% | 2.07% | 2.96% | 6.10% | 9.00% | 16.28% |
| EPS | -0.02 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
| EPS Diluted | -0.02 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
| Weighted Avg Shares Out | 84.23M | 84.15M | 83.94M | 77.53M | 64.07M | 44.90M | 69.58M | 69.58M |
| Weighted Avg Shares Out (Dil) | 84.23M | 86.09M | 84.94M | 77.83M | 64.17M | 44.90M | 69.58M | 69.58M |
Source: https://incomestatements.info
Category: Stock Reports